TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The participant had a diagnosis of Gaucher Type I disease and a documented deficiency of glucocerebrosidase activity by enzyme assay and was willing and able to provide written informed consent prior to initiating any study-related procedures;~* The participant was 18 to 65 years old and weighed between 50 and 120 kilogram (kg) at enrollment;~* The participant had the following symptoms of Gaucher disease identified within 28 days of enrollment (at screening);~  * Anemia - indicated by hemoglobin measurements taken during the screening phase (8 to 10 gram per deciliter (g/dL) if female, 8 to 11 g/dL if male);~ * Thrombocytopenia - indicated by platelet count measurements taken during the screening phase (60000 to 100000 per cubic millimeter);~ * Splenomegaly, as indicated by magnetic resonance imaging (MRI) or spiral computed tomography (CT) (\>= 10 multiples of normal);~* Female participants of child-bearing potential must had a documented negative serum pregnancy test prior to dosing. Female participants agreed to use a reliable method of birth control throughout duration of trial.~Exclusion Criteria:~* Participant had a partial or total splenectomy or infarcted areas of the spleen;~* Participant had documented prior bleeding varices or liver infarction;~* Participant received miglustat within 12 months prior to study enrollment;~* The participant had received an investigational product within 30 days prior to study enrollment;~* Participant had neurologic or pulmonary involvement;~* Participant had new pathological bone involvement or bone crisis in the 12 months prior to enrollment;~* Participant was transfusion-dependent;~* Participant had a documented etiology of anemia due to causes other than Gaucher disease;~* The participant had cardiac functional and/or anatomical abnormalities, a history of cancer or tested positive for human immunodeficiency virus (HIV) antibody or Hepatitis;~* Participant had a clinically significant disease, other than Gaucher disease, including cardiovascular, renal, hepatic, gastrointestinal, pulmonary, neurologic, endocrine, metabolic, or psychiatric disease, other medical conditions, or serious intercurrent illnesses that, in the opinion of the Investigator, might preclude participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Eliglustat tartrate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have completed their participation in a randomized qualifying study of CP-690,550 for the treatment of rheumatoid arthritis~Exclusion Criteria:~* Serious medical conditions that would make treatment with CP-690,550 potentially unsafe

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CP-690,550 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age at least 18 years at the time of signing informed consent. For Algeria only: age at least 19 years at the time of signing informed consent~* Type 2 diabetes subjects clinically diagnosed for at least 12 months prior to the day of screening (Visit 1)~* Treated with basal insulin for at least 90 days prior to the day of screening (Visit 1). The following basal insulin are allowed : insulin analogue once daily (OD) Neutral Protamine Hagedorn (NPH) OD or BID (twice daily)~* Treatment with metformin with or without one additional OAD (oral antidiabetic drug) for at least 90 days prior to the day of screening (Visit 1) Metformin must be at a stable dose of at least 1500 mg daily or maximum tolerated dose for at least 60 days prior to screening (Visit 1) One additional OAD:Sulphonylurea/Glinides/ a-glucosidase inhibitors/Dipeptidyl-peptidase-4 inhibitors/Sodium glucose co-transporter 2 (SGLT2) inhibitors (if applicable)~* HbA1c (glycosylated haemoglobin) 7.5%-10.0% (both inclusive) by central laboratory analysis at screening (Visit 1)~* Able and willing to intake three main meals daily (breakfast, lunch and main evening meal) throughout the trial. Definition of main meal as judged by the investigator~Exclusion Criteria:~* Previous insulin intensification regimen for more than 14 days: premixed insulin thrice daily, basal-bolus regimen or continuous subcutaneous insulin infusion (CSII). Treatment during hospitalisation or during gestational diabetes is allowed for periods longer than 14 days~* Anticipated initiation or change in concomitant medications for more than 14 consecutive days or on a frequent basis known to affect weight or glucose metabolism (e.g. orlistat, thyroid hormones, systemic corticosteroids)~* Impaired liver function, defined as alanine aminotransferase (ALT) equal to or above 2.5 times upper normal limit at screening (Visit 1)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIAsp 30 TID (Type: EXPERIMENTAL): None
- BIAsp 30 BID (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent.~* Histological diagnosis of breast cancer.~* Node positive operable breast cancer (stages II-III).~* Breast cancer surgery, consisting of radical mastectomy or conservative surgery, plus lymphadenectomy with at least 6 extirpated nodes. Surgery must have happened in the 8 weeks prior to randomisation.~* Age \>=18 and \<= 70 years old.~* Negative pregnancy test. Adequate contraceptive method during the study participation.~* Performance status of 90-100 (Karnofsky index) or ECOG \<=1.~* Haemoglobin \>= 10 g/dl; neutrophils \> 1,500/cc; platelets \> 100,000/cc.~* Adequate hepatic function with bilirubin, SGOT and SGPT \< 1.5 x upper normal limit (UNL).~* Adequate cardiac function documented by left ventricular ejection fraction (LVEF).~* Adequate renal function with creatinine \< 1.5 mg/dl.~Exclusion Criteria:~* Previous chemotherapy, hormone therapy and/or radiotherapy for breast cancer.~* Bilateral breast cancer. Lobular in situ carcinoma.~* Previous or current malignancies, except for basal skin carcinoma, cervical in situ carcinoma or superficial bladder carcinoma, adequately treated.~* History of arrhythmias and/or congestive heart failure or cardiac blocking grade 2-3; history of myocardial infarction in 6 months before recruitment.~* Inability for treatment and study compliance.~* Pregnant or lactating women.~* Active infection.~* History of hypersensitivity to cremophor or cyclosporine.~* Pre-existing grade 2 motor or sensorial neurotoxicity (National Cancer Institute Common Toxicity Criteria \[NCI CTC\]).~* Hormonal receptor status not determined.~* Any other criteria which, in investigator's opinion, may jeopardize patient's security or compliance.~* Administration of other investigational product in the 30 days prior to randomisation; current participation in another clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fluorouracil+Epirubicin+Cyclophosphamide (Type: ACTIVE_COMPARATOR): 5-FU+4-Epirubicin+Cyclophosphamide
- FEC followed by Paclitaxel (Type: EXPERIMENTAL): 5-FU+4-Epirubicin+Cyclophosphamide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RCT of Pulp Capping Over Carious Exposure in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age 18-55 years~* 1st and 2nd permanent molars~* Proximal caries to inner 1/3 of dentin (bite-wing)~* Apex closed, no periapical changes (apical radiograph)~* No periodontal pockets deeper than 4mm~* Medical history non-contributory (incl.pregnancy)~* No medication (no antibiotics during last month)~* No signs or symptoms more severe than reversible pulpitis~* Positive response to electrical pulp test(EPT) or cold test~* Written consent Inclusion requires compliance with all the criteria listed~Exclusion criteria:~* During the treatment there will be no pulpal exposure~* The bleeding of the exposed pulp cannot be controled in 10 minutes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Capping over carious exposure with Dycal (Type: ACTIVE_COMPARATOR): Total caries removal. In case of pulp exposure Direct Pulp capping with (Dycal®, Dentsply DeTrey GmbH, Konstanz, Germany)
- Capping over carious exposure with WMTA (Type: EXPERIMENTAL): Total caries removal. In case of pulp exposure Direct Pulp capping with Mineral Trioxide Aggregate White ProRoot® (WMTA) (DENTSPLY, Tulsa Dental, Tulsa, OK, USA)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A maximum body weight of 85.0 kg.~* A minimum body weight of 10 kg for participants aged 2 years to less than 3 years old.~* If female and post-menarchal, or 12 years or older, the subject has a negative urine pregnancy test within 24 hours before surgery.~* Having completed either dental surgery or tonsillectomy with or without adenoidectomy surgery (age group: 6 to less than 18 years of age).~* Having completed ear, nose, or throat surgery (including but not limited to tonsillectomy (age group: 2 to less than 3 years of age).~* Participant aged 6 to less than 18 years has a post-operative pain intensity score greater than or equal to 4 on the Color Analog Scale (CAS) as a result of the surgical procedure or the participant has a pain level that the usual standard of care following the surgical procedure (which reliably produces moderate to severe pain) requires opioid treatment.~* Participant aged 2 years to less than 6 years has a pain level following a surgical procedure that reliably produces moderate to severe pain, for which the usual standard of care requires opioid treatment.~* Participant is alert, orientated, and able to follow commands and complete the post-operative required procedures.~Exclusion Criteria:~* History of brain injury.~* Clinically relevant abnormal ECG.~* Clinically unstable vital signs and/or a saturation of oxygen saturation (SpO2) less than 93%. During surgery SpO2 may decrease \<93%.~* Clinically relevant abnormal values for clinical chemistry, hematology, or urinalysis at enrollment.~* Body temperature above 38.5°C within 48 hours prior to dosing.~* Positive drugs of abuse test result.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Tapentadol (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Pentoxifylline and Vitamin E on Radiotherapy-induced Toxicity in Head & Neck Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients~* Measurable disease~* Patients with squamous cell carcinoma of the head and neck eligible for treatment with concurrent chemo- radiotherapy~* Able to understand and willing to sign a written informed consent document~Exclusion Criteria:~* Pregnant or lactating women, since imaging cannot be done in this setting.~* Patients treated with vitamin E and/ or pentoxifylline for any other indication~* Patients with recent cerebral and/or retinal hemorrhage~* Patients who have previously exhibited intolerance to pentoxifylline or methylxanthines such as caffeine, theophylline, and theobromine.~* Patients treated with oral anticoagulants.~* Absolute neutrophil count ≤1.5×109/L~* Platelets ≤100×109/L~* AST ≥ 2.5 X institutional upper limit normal (ULN)~* Serum creatinine ≥ 1.5 mg% for males \& 1.4 mg% for females~* Serum bilirubin ≥ 1.5X institutional upper limit normal (ULN)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): Platinum based concurrent chemoradiotherapy \[cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks\] .~Pentoxifylline 400 mg oral tablets twice daily for 7 weeks. Vitamin E 1000 mg oral capsules once daily for 7 weeks.
- Control Group (Type: ACTIVE_COMPARATOR): Platinum based concurrent chemoradiotherapy \[cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks\] .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Artificial Balneotherapy, Phototherapy and Artificial Balneophototherapy in the Treatment of Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* be more than 18 years-old,~* have more than one plaque on the skin,~* medically diagnosed as plaque psoriasis over a year ago and,~* without concurrent topical treatment for Psoriasis (by own choice).~Exclusion Criteria:~* pregnancy,~* skin carcinoma,~* severe diabetes mellitus,~* uncontrolled chronic pathologies and/or severe cardiac/renal insufficiency and/or acute infections.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: NO_INTERVENTION): The control group plaques did not receive any treatment.
- phototherapy group (Type: EXPERIMENTAL): Twelve sessions of phototherapy (UV-B) applied on psoriatic plaques according to individual initial evaluation of Minimal Erythema Dose (MED).
- balneotherapy (Type: EXPERIMENTAL): Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L) applied on psoriatic plaques.
- balneophototherapy (Type: EXPERIMENTAL): Twelve sessions of both balneotherapy and phototherapy treatments on the same conditions described above applied on psoriatic plaques.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* stage IV non-squamous non-small cell lung cancer;~* asymptomatic, untreated brain metastasis;~* ECOG performance status 0-1.~Exclusion Criteria:~* previous treatment for brain metastasis;~* history of migraine or epilepsy;~* previous treatment with angiogenesis inhibitors;~* for cohort 2, previous first line treatment with Avastin or Tarceva;~* current or recent use of aspirin (\>325mg/day) or full-dose anticoagulants or thrombolytic agent for therapeutic purposes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-55~* Physically healthy and not currently pregnant~* Primary Diagnosis of OCD~* Sufficient severity of symptoms~* Able to provide consent~Exclusion Criteria:~* Psychiatric conditions that make participation unsafe~* Currently on psychotropic medication~* Medical conditions that make participation unsafe~* Allergy to ketamine~* Any metal in the body

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): 0.5mg/kg IV ketamine infusion over 40 minutes then IV saline infusion over 40 minutes
- Group B (Type: ACTIVE_COMPARATOR): IV saline infusion over 40 minutes then 0.5mg/kg IV ketamine infusion over 40 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Serum phosphate level greater than (\>) 5.5 milligram per deciliter (mg/dL) (1.78 millimole per liter \[mmol/L\]) after discontinuation of current phosphate binder therapy~* Men or women 18 years or older~Exclusion Criteria:~* Have active dysphagia or swallowing disorder or a predisposition to or current bowel obstruction, ileus, or severe gastrointestinal motility disorders including severe constipation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to Genz-644470 tablet orally three times a day (TID) with meals for 3 weeks.
- Genz-644470 2.4 Grams Per Day (g/day) (Type: EXPERIMENTAL): Genz-644470 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
- Genz-644470 4.8 g/day (Type: EXPERIMENTAL): Genz-644470 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
- Genz-644470 7.2 g/day (Type: EXPERIMENTAL): Genz-644470 7.2 g/day tablets dosed orally TID with meals for 3 weeks.
- Sevelamer Carbonate 2.4 g/day (Type: ACTIVE_COMPARATOR): Sevelamer Carbonate 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
- Sevelamer Carbonate 4.8 g/day (Type: ACTIVE_COMPARATOR): Sevelamer Carbonate 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
- Sevelamer Carbonate 7.2 g/day (Type: ACTIVE_COMPARATOR): Sevelamer Carbonate 7.2 g/day tablets dosed orally TID with meals for 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete